Rubicon Organics Past Earnings Performance
Past criteria checks 0/6
Rubicon Organics has been growing earnings at an average annual rate of 25.8%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 48.1% per year.
Key information
25.8%
Earnings growth rate
33.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 48.1% |
| Return on equity | -9.5% |
| Net Margin | -8.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Rubicon Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 41 | -3 | 14 | 0 |
| 31 Mar 24 | 40 | -3 | 15 | 0 |
| 31 Dec 23 | 40 | -2 | 14 | 0 |
| 30 Sep 23 | 41 | -5 | 16 | 0 |
| 30 Jun 23 | 42 | -2 | 16 | 0 |
| 31 Mar 23 | 39 | -3 | 16 | 0 |
| 31 Dec 22 | 36 | -4 | 16 | 0 |
| 30 Sep 22 | 31 | -2 | 15 | 0 |
| 30 Jun 22 | 28 | -8 | 14 | 0 |
| 31 Mar 22 | 24 | -12 | 15 | 0 |
| 31 Dec 21 | 23 | -15 | 15 | 0 |
| 30 Sep 21 | 21 | -18 | 15 | 0 |
| 30 Jun 21 | 17 | -18 | 15 | 0 |
| 31 Mar 21 | 13 | -15 | 13 | 0 |
| 31 Dec 20 | 9 | -14 | 12 | 0 |
| 30 Sep 20 | 5 | -12 | 11 | 0 |
| 30 Jun 20 | 1 | -11 | 10 | 0 |
| 31 Mar 20 | 0 | -12 | 11 | 0 |
| 31 Dec 19 | 0 | -11 | 11 | 0 |
| 30 Sep 19 | -1 | -9 | 10 | 0 |
| 30 Jun 19 | -1 | -10 | 11 | 0 |
| 31 Mar 19 | 0 | -25 | 10 | 0 |
| 31 Dec 18 | 0 | -25 | 9 | 0 |
| 30 Sep 18 | 2 | -26 | 9 | 0 |
| 30 Jun 18 | 1 | -23 | 6 | 0 |
| 31 Mar 18 | 1 | -8 | 7 | 0 |
| 31 Dec 17 | 1 | -6 | 5 | 0 |
| 31 Dec 16 | 2 | 2 | 0 | 0 |
Quality Earnings: R07 is currently unprofitable.
Growing Profit Margin: R07 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R07 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare R07's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: R07 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: R07 has a negative Return on Equity (-9.52%), as it is currently unprofitable.